8-K: Lineage Cell Therapeutics Reports Q2 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics announced its second quarter 2024 financial results, highlighting clinical progress with OpRegen and preparations for the OPC1 clinical study.

Summary

• Lineage Cell Therapeutics reported a net loss of $5.8 million for the second quarter of 2024, or $0.03 per share, compared to a net loss of $5.2 million for the same period in 2023.
• Total revenue for the quarter was $1.4 million, a decrease from $3.2 million in the second quarter of 2023, primarily due to reduced collaboration and licensing revenue from Roche.
• Operating expenses decreased to $7.3 million from $8.2 million in the same quarter of the previous year, with R&D expenses down by $1.0 million.
• The company's cash, cash equivalents, and marketable securities totaled $38.5 million as of June 30, 2024, which is expected to fund operations into Q4 2025.
• Lineage is progressing its OpRegen program in collaboration with Roche and Genentech, including a Phase 2a study for geographic atrophy (GA).
• The company is also preparing to initiate the DOSED clinical study for OPC1, a treatment for spinal cord injuries.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with positive clinical data and a strong partnership, but also declining revenues and increasing losses. The company's cash runway is a positive, but the need for future capital raises is likely.

Positives

• OpRegen showed positive long-term clinical data with visual acuity gains at 24 months.
• The collaboration with Roche and Genentech is progressing well, with a new services agreement in place.
• Lineage is actively preparing to return OPC1 to the clinic for spinal cord injury treatment.
• The company's cash runway extends into Q4 2025.
• Lineage's continued inclusion in the Russell 3000 Index may broaden investor awareness.

Negatives

• Total revenues decreased by $1.8 million compared to the same period in 2023.
• The net loss increased by $0.6 million compared to the same period in 2023.
• Research and development expenses decreased by $1.0 million, which may indicate a slowdown in some programs.
• The company reported a loss from operations of $5.9 million for the quarter.

Risks

• The company may need to allocate cash to unexpected events, potentially shortening the cash runway.
• Clinical trials may not progress as expected due to factors within and outside of the company's control.
• Positive findings in early studies may not predict success in later clinical trials.
• Competing therapies could impact the commercial potential of OpRegen.
• The ongoing Israel-Hamas war may impact manufacturing processes.
• Lineage may not be able to manufacture sufficient clinical quantities of its product candidates.

Future Outlook

The company expects its current cash position to support planned operations into Q4 2025 and is focused on advancing its clinical programs, particularly OpRegen and OPC1.

Management Comments

• The second quarter was highlighted by clinical and preclinical execution alongside expanded awareness and data updates on our lead program, stated Brian M. Culley, Lineage CEO.
• We are excited about our validating partnership and the collective expertise of the team at Roche and Genentech, as well as their ongoing leadership of the OpRegen program, added Mr. Culley.
• We continue to support the ongoing Phase 2a clinical study and also have initiated activities under the recently established services agreement with Genentech, enabling our partners to take advantage of our cell transplant expertise, said Mr. Culley.
• We are focused on activities in support of returning our second cell transplant program, OPC1, into the clinic this year for the treatment of spinal cord injury, said Mr. Culley.
• Our continued inclusion within the Russell 3000 Index, can help our efforts to broaden investor awareness of, and support for, Lineage as a uniquely positioned cell transplant company, added Mr. Culley.

Industry Context

This announcement highlights the ongoing progress in the cell therapy field, particularly in the areas of retinal diseases and spinal cord injuries. The collaboration with Roche and Genentech underscores the growing interest from large pharmaceutical companies in cell-based therapies. The focus on internal cGMP capabilities also reflects the industry's need for robust manufacturing processes.

Comparison to Industry Standards

• The reported 5.5 letter BCVA gain at 24 months for OpRegen is a positive result, comparing favorably to other early-stage cell therapy trials for geographic atrophy, although direct comparisons are difficult due to varying trial designs and patient populations.
• Companies like Iveric Bio (now part of Astellas) and Apellis Pharmaceuticals are also developing treatments for geographic atrophy, but with different mechanisms of action, making direct comparisons challenging.
• The progress of OPC1 in spinal cord injury is notable, as this area has seen limited therapeutic advancements, with companies like Neuronyx also exploring cell-based therapies for spinal cord injuries.
• Lineage's cash runway into Q4 2025 is relatively standard for a clinical-stage biotech company, but the company will likely need to raise additional capital in the future to support its ongoing clinical programs.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased revenue.
• Employees may be encouraged by the progress of clinical programs and the partnership with Roche and Genentech.
• Patients with geographic atrophy and spinal cord injuries may be hopeful about the potential of OpRegen and OPC1.
• The collaboration with Roche and Genentech may strengthen the company's position with suppliers and creditors.

Next Steps

• Continue execution under the collaboration with Roche and Genentech.
• Advance the Phase 2a clinical study of OpRegen for geographic atrophy.
• Initiate the DOSED clinical study for OPC1 for spinal cord injury.
• Continue to develop and expand internal cGMP capabilities.

Key Dates

Keywords

cell therapy, OpRegen, OPC1, geographic atrophy, spinal cord injury, clinical trial, biotechnology, Roche, Genentech, retinal pigment epithelial cells, oligodendrocyte progenitor cells